secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001104659-24-028704
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports $444M net loss for 2023; Amtagvi approved and launched Feb 2024
-------------------------------------------------------------------------------

- FDA approved Amtagvi (lifileucel) on Feb 16, 2024 — first T cell therapy for a solid tumor (advanced melanoma).
- Net loss $444.0M ($1.89/share) for 2023 vs $395.9M ($2.49/share) in 2022; revenue $1.2M (first Proleukin sales).
- Cash $346.3M at Dec 31, 2023; post Feb 2024 equity raise ~$485.2M, expected to fund operations into H2 2025.
- ~30 U.S. ATCs onboarded; ~50 expected by May 2024; at least 20 patients in process since approval.
- MAA for EU expected H1 2024; UK and Canada submissions H2 2024; clinical hold on IOV-LUN-202 NSCLC trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/0001104659-24-028704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/tm247491d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-028704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer